GC
SLS icon

Grange Capital’s SELLAS Life Sciences SLS Stock Holding History

Grange Capital’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.7K Buy
17,651
+1,650
+10% +$7.38K 0.07% 46
2025
Q4 		$60.3K Buy
16,001
+2,500
+19% +$4.86K 0.06% 47
2025
Q3 		$21.7K Hold
13,501
– – 0.02% 45
2025
Q2 		$29.6K Hold
13,501
– – 0.03% 48
2025
Q1 		$14.6K Buy
+13,501
New +$16K 0.02% 46

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Grange Capital's SLS Position: Q1 2026 in Review

Grange Capital increased its SELLAS Life Sciences (SLS) stake by 10% in Q1 2026, buying an estimated $7.38K and bringing the position to 17,651 shares worth $74.7K. The position accounts for 0.07% of the portfolio, ranked #46.

Grange Capital first reported a position in SLS in Q1 2025 and has held it in 5 quarters since. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Grange Capital held 17,651 shares of SELLAS Life Sciences worth $74.7K as of Q1 2026.
  • Grange Capital bought 1,650 SELLAS Life Sciences shares in Q1 2026, an estimated $7.38K.
  • SELLAS Life Sciences made up 0.07% of Grange Capital's portfolio in Q1 2026, its #46 holding.
  • Grange Capital first reported a position in SELLAS Life Sciences in Q1 2025 and has held it in 5 quarters since.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Grange Capital's 13F filing for Q1 2026, filed 28 Apr 2026.